Skip to content
You are now leaving to visit

Ionis licenses investigational Alzheimer’s therapy

– IONIS-MAPT Rx is designed to selectively reduce production of the protein tau in the central nervous system – Ionis earns $45 million license fee CARLSBAD, Calif. , Dec. 19, 2019 /PRNewswire/ —  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today